Insider Trading July 2, 2026 07:24 PM

CERUS CFO Executes Pre-Arranged Share Sales Amid Financial Restructuring

Kevin Green's transactions under Rule 10b5-1 plan coincide with company's debt refinancing and Q1 earnings beat.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CERS

CERUS CORP (NASDAQ: CERS) Chief Financial Officer Kevin Green executed a series of share transactions on June 30, 2026, selling 33,676 shares at a weighted average price of $2.9429. The sales, totaling $99,105, were conducted under a pre-established Rule 10b5-1 trading plan designed to cover tax withholding obligations and brokerage fees related to restricted stock unit vesting. This transaction is non-discretionary in nature. Concurrently, Mr. Green disposed of 63,600 shares at a nominal price of $0.00. Following these activities, his direct ownership stands at 1,062,188 shares. The executive activity occurs against a backdrop of recent corporate developments, including a first-quarter earnings beat and a significant debt refinancing agreement with MidCap Financial.

CERUS CFO Executes Pre-Arranged Share Sales Amid Financial Restructuring
CERS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CFO Kevin Green executed a non-discretionary sale of 33,676 shares totaling $99,105 under a Rule 10b5-1 plan, leaving him with 1,062,188 direct shares.
  • Cerus Corporation reported a Q1 2026 EPS of -$0.01, beating estimates by 80%, and secured a $110 million debt facility with MidCap Financial to reduce interest expenses.
  • The stock traded near its 52-week high of $3.21 following a 103% annual return, though the company remains unprofitable with $216.56 million in revenue.

Kevin Green, serving as the Chief Financial Officer for CERUS CORP (NASDAQ: CERS), executed a transaction involving the sale of 33,676 shares of the company's common stock on June 30, 2026. The aggregate value of these sales reached $99,105, calculated based on a weighted average price of $2.9429 per share. The individual execution prices for this batch of shares fluctuated between $2.84 and $3.03.


The timing of this sale aligns with a period where the stock was trading in proximity to its 52-week high of $3.21. This price level follows a substantial 103% return recorded over the preceding year. The transaction was facilitated through a Rule 10b5-1 trading plan, a mechanism typically utilized to automate sales and avoid allegations of insider trading. According to the filing, the specific purpose of this plan was to satisfy statutory tax withholding requirements and cover associated brokerage fees linked to the vesting of restricted stock units. Consequently, this transaction is classified as non-discretionary on the part of Mr. Green.


On the identical date, Mr. Green also divested 63,600 shares of common stock at a price of $0.00 per share. Post these reported activities, Mr. Green's direct holding in Cerus common stock stands at 1,062,188 shares. The broader corporate context for Cerus Corporation includes a market valuation of $627 million. Financially, the company remains unprofitable, having reported revenue of $216.56 million. Independent analysis from InvestingPro suggests that CERS may currently be slightly overvalued relative to its calculated Fair Value. Detailed valuation models, which incorporate 17 distinct methodologies, are available to investors seeking to determine the intrinsic worth of the stock.


Recent corporate developments provide additional context to the executive activity. Cerus Corporation reported its first-quarter earnings for 2026, which surpassed market expectations. The company achieved an earnings per share (EPS) of -$0.01, representing an 80% positive surprise compared to the anticipated -$0.05. Revenue also exceeded projections, coming in at $59.9 million against an expected $56.17 million, marking a 6.64% positive surprise.


Furthermore, Cerus secured a new debt facility with MidCap Financial, providing access to up to $110 million in capital. This facility comprises a 5-year term loan and an asset-backed revolving loan. The refinancing structure is projected to reduce annual cash interest expenses by up to $3.5 million and decrease the outstanding term loan balance by approximately $30 million. These financial maneuvers highlight ongoing efforts to optimize the company's capital structure and operational performance.


Market data indicates the stock closed at 3.17, reflecting a gain of 0.17 or 5.67%. After-hours trading showed further movement, with the stock at 3.168, up 0.008 or 0.25%. The stock's performance over the past year underscores significant volatility and investor interest, despite the company's current unprofitable status. The intersection of executive share sales, financial restructuring, and earnings beats presents a complex picture for stakeholders monitoring Cerus Corporation.


Key Points:

  • Executive Transactions: CFO Kevin Green sold 33,676 shares for $99,105 under a Rule 10b5-1 plan, maintaining a direct holding of 1,062,188 shares.
  • Financial Restructuring: Cerus secured a $110 million debt facility with MidCap Financial, aimed at reducing interest expenses and lowering debt balances.
  • Earnings Performance: The company reported a Q1 2026 EPS of -$0.01, beating estimates by 80%, with revenue of $59.9 million surpassing projections by 6.64%.

Risks and Uncertainties:

  • Valuation Discrepancy: Analysis suggests CERS may be slightly overvalued relative to its Fair Value, posing a risk for investors relying on current price levels.
  • Profitability Status: The company remains unprofitable with reported revenue of $216.56 million, indicating ongoing challenges in achieving sustained earnings.
  • Debt Obligations: While the new facility offers relief, the reliance on asset-backed revolving loans and term loans introduces refinancing risks and interest rate exposure.

Risks

  • Valuation concerns arise as analysis suggests CERS may be slightly overvalued relative to its Fair Value, despite recent price appreciation.
  • The company's unprofitable status and reliance on debt refinancing highlight ongoing financial stability challenges in the biotech sector.
  • Market volatility and the stock's proximity to 52-week highs introduce uncertainty regarding future price movements and investor sentiment.

More from Insider Trading

Immunome Director Barchas Executes $4.39M Stock Sale Amid Regulatory Milestones Jul 2, 2026 Insider Accumulation at Jewett-Cameron: AJB Funds and Bradleys Purchase $25,871 in JCTC Shares Jul 2, 2026 EverCommerce President Executes $259K Stock Sale Under Pre-Approved Plan Jul 2, 2026 Insider Activity: Smolyansky Offloads $5.18M in Lifeway Foods Stock Amid Strong Financials Jul 2, 2026 EverCommerce CEO Eric Remer Executes Stock Sales Under Pre-Arranged Plan Jul 2, 2026